Cereno Scientific initiates collaboration with the Pulmonary and Vascular Research Institute (PVRI)
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, with its lead program CS1 currently being evaluated in a Phase II clinical study in the rare disease Pulmonary Arterial Hypertension (PAH), today announced that the Company will join the PVRI Roundtable (Pulmonary and Vascular Research Institute). Cereno will, amongst other things, participate in PVRI’s Innovative Drug Development Initiative (IDDI), addressing the most challenging issues faced by pharma, researchers, regulators, and clinicians and join a task force to stimulate awareness of new research in Pulmonary Hypertension. The collaboration comes on the back of Cereno’s participation at the PVRI Annual World Congress on Pulmonary Vascular Disease and The PVRI Drug Discovery & Development Symposium.
“I am pleased to announce that Cereno has joined the PVRI Roundtable, by exclusive invitation from the organization. This membership alliance between the industry and the PVRI will allow Cereno to work closely with the organization and other industry members to raise awareness of pulmonary vascular disease and access PVRI’s network of over 6,000 pulmonary hypertension professionals in more than 100 different countries, including clinicians, clinical investigators, basic scientists, academics and regulators”, said Sten R. Sörensen, CEO, Cereno Scientific.
“By formalizing our relationship with PVRI we will increase our exposure towards academic and industry stakeholders in the field of pulmonary vascular disease, with whom we can collaborate to drive innovation of new treatments to the benefit of patients and society, in these debilitating diseases”, said Björn Dahlöf, CSO, Cereno Scientific.
By joining the PVRI Roundtable, Cereno will be able to further increase the exposure for the Company’s pipeline, comprising late-stage Phase II drug candidate CS1, a HDAC inhibitor with epigenetic effects for the treatment of the rare disease PAH, CS014, an HDAC inhibitor with epigenetic effects, being developed for thrombosis prevention with a first-in-human Phase I study planned to start in Q2 2024 and the Company’s 3rd asset CS585, a novel IP receptor agonist. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding.
About the PVRI
The Pulmonary Vascular Research Institute (PVRI) is a charity that brings the best medical professionals in the world together who have an interest in pulmonary hypertension or pulmonary vascular disease. The PVRI has established itself as the professional international organization fighting pulmonary vascular disease on a global scale. PVRI’s vision is to reduce the global burden of pulmonary vascular disease, through their mission to advocate, collaborate and educate. Their network has expanded to over 6,300 people spread across 103 different countries worldwide, including an active membership of 1,250 pulmonary hypertension professionals.
PVRI organizes two large annual scientific meetings aimed at PVRI members, drug regulatory bodies and the pharmaceutical industry as a whole; the PVRI Annual World Congress on Pulmonary Vascular Disease and The PVRI Drug Discovery & Development Symposium.
The PVRI is a not-for-profit organisation registered in the UK as a charity and a limited company, led by a Board of Trustees.
For further information, please contact:
Henrik Westdahl, Director IR & Communications
Email: henrik.westdahl@cerenoscientific.com
Phone: +46 70-817 59 96
Sten R. Sörensen, CEO
Email: sten.sorensen@cerenoscientific.com
Phone: +46 73-374 03 74
About Cereno Scientific AB
Cereno Scientific develops innovative treatments for rare and common cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q3 2024. Since January 2024, we are delighted that the FDA´s Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. In April 2024, Cereno submitted a Clinical Trial Application (CTA) for a Phase I First-in-Human-Study, expected to start during Q2 2024. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding, which also has been recognized in the medical community. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.